Table IV.
Multivariate predictions of survival.
| PFS
|
OS
|
|||||
|---|---|---|---|---|---|---|
| Category | Hazard ratio | 95% CI | P-value | Hazard ratio | 95% CI | P-value |
| Age (years) | ||||||
| <65 vs. ≥65 | 1.23 | 0.67–2.28 | 0.506 | 1.18 | 0.64–2.29 | 0.633 |
| Gender | ||||||
| Female vs. male | 2.86 | 0.75–10.89 | 0.124 | 1.24 | 0.27–6.75 | 0.808 |
| Histologic type | ||||||
| Non-adeno vs. adeno | 0.80 | 0.41–1.56 | 0.521 | 1.59 | 0.81–3.14 | 0.182 |
| Clinical stage | ||||||
| IV vs. III | 0.64 | 0.35–1.15 | 0.134 | 0.80 | 0.40–1.60 | 0.534 |
| Performance status | ||||||
| 0–1 vs. 2 | 2.02 | 1.13–3.61 | 0.017 | 2.13 | 1.14–3.98 | 0.018 |
| Smoking history | ||||||
| None vs. current + former | 1.48 | 0.39–5.56 | 0.57 | 1.38 | 0.25–7.61 | 0.706 |
| Serum CEA level (ng/ml) | ||||||
| <5 vs. ≥5 | 0.41 | 0.24–0.78 | 0.007 | 0.55 | 0.25–1.21 | 0.554 |
| Serum CYFRA 21-1 level (ng/ml) | ||||||
| <3.3 vs. ≥3.3 | 1.93 | 1.09–3.44 | 0.025 | 2.76 | 1.38–5.53 | 0.004 |
| EGFR mutation (n=84) | ||||||
| Negative vs. positive | 0.22 | 0.11–0.42 | <0.001 | 0.53 | 0.28–1.004 | 0.051 |
PFS, progression-free survival; OS, overall survival; TKI, tyrosine kinase inhibitor; CEA, carcinoembryonic antigen; CYFRA 21-1, cytokeratin-19 fragments; EGFR, epidermal growth factor receptor.